Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis
This study is currently recruiting participants.
Verified February 2013 by Centre hospitalier de l'Université de Montréal (CHUM)
Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators:
Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Erasme University Hospital
Information provided by (Responsible Party):
Centre hospitalier de l'Université de Montréal (CHUM)
ClinicalTrials.gov Identifier:
NCT01318590
First received: March 17, 2011
Last updated: February 25, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if celiac bloc (with injection of steroid and local anesthetic) is superior to a sham procedure for pain control and quality of life improvement in patient with chronic pancreatitis and abdominal pain.
| Condition | Intervention | Phase |
|---|---|---|
|
Pancreatitis, Chronic |
Drug: Bupivacaine & Triamcinolone Acetonide Other: No intervention except EUS procedure |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Supportive Care |
| Official Title: | Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis |
Resource links provided by NLM:
Drug Information available for:
Triamcinolone diacetate
Triamcinolone acetonide
Triamcinolone
Triamcinolone hexacetonide
Bupivacaine hydrochloride
Bupivacaine
U.S. FDA Resources
Further study details as provided by Centre hospitalier de l'Université de Montréal (CHUM):
Primary Outcome Measures:
- Pain reduction on Likert scale [ Time Frame: each month for six months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Quality of Life (QOL) score [ Time Frame: each month for six months ] [ Designated as safety issue: No ]the digestive disease QOL questionnaire 15 (DDQ-15) is used to analyze QOL
| Estimated Enrollment: | 100 |
| Study Start Date: | March 2011 |
| Estimated Study Completion Date: | August 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Celiac bloc |
Drug: Bupivacaine & Triamcinolone Acetonide
EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis
|
| Sham Comparator: Conservative treatment |
Other: No intervention except EUS procedure
EUS procedure without any drug injection
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- abdominal pain compatible with pancreatic ethiology since at least 3 months
- chronic pancreatitis on Computed Tomography (CT), Endoscopic Retrograde Cholangiopancreatography (ERCP) or EUS
- EUS feasible
- inform consent
Exclusion Criteria:
- pregnant women
- allergy to local anesthetic
- acute pancreatitis in the last 2 weeks
- suspicious lesion on pancreatic EUS examination
- celiac bloc in the last 3 months
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01318590
Contacts
| Contact: Anand V Sahai, MD | 1(514)8908000 ext 34373 | anand.sahai@sympatico.ca |
| Contact: Mariana Usatii | 1(514)8908000 | m_usatii@yahoo.com |
Locations
| Belgium | |
| Erasme Hospital | Recruiting |
| Brussels, Belgium, B1070 | |
| Contact: Jacques Deviere, MD +3225553712 jacques.deviere@erasme.ulb.ac.be | |
| Contact: Pierre Eisendrath, MD +3225553712 pierreeisendrath@me.com | |
| Sub-Investigator: Pierre Eisendrath, MD | |
| Sub-Investigator: Jacques Deviere, MD | |
| Canada, Quebec | |
| CHUM | Recruiting |
| Montreal, Quebec, Canada | |
| Contact: Anand V Sahai, MD 1(514)8908000 ext 34373 anand.sahai@sympatico.ca | |
| Principal Investigator: Anand V Sahai, MD | |
Sponsors and Collaborators
Centre hospitalier de l'Université de Montréal (CHUM)
Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Erasme University Hospital
Investigators
| Principal Investigator: | Anand V Sahai, MD | CHUM |
More Information
No publications provided
| Responsible Party: | Centre hospitalier de l'Université de Montréal (CHUM) |
| ClinicalTrials.gov Identifier: | NCT01318590 History of Changes |
| Other Study ID Numbers: | CE 10 160 |
| Study First Received: | March 17, 2011 |
| Last Updated: | February 25, 2013 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Centre hospitalier de l'Université de Montréal (CHUM):
|
Pancreatitis, Chronic Abdominal Pain Celiac bloc Endosonography |
Additional relevant MeSH terms:
|
Pancreatitis Pancreatitis, Chronic Pancreatic Diseases Digestive System Diseases Bupivacaine Triamcinolone hexacetonide Triamcinolone Triamcinolone Acetonide Triamcinolone diacetate Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs |
Pharmacologic Actions Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Immunosuppressive Agents Immunologic Factors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 22, 2013